A randomized trial comparing radical prostatectomy plus endocrine therapy versus external beam radiotherapy plus endocrine therapy for locally advanced prostate cancer: Results at median follow-up of 102 months

Japanese Journal of Clinical Oncology

Volumn 36, Issue 12, 2006, Pages 789-793

  Akakura, Koichiro ^a,g   Suzuki, Hiroyoshi ^a   Ichikawa, Tomohiko ^a   Fujimoto, Hiroyuki ^b   Maeda, Osamu ^c   Usami, Michiyuki ^c   Hirano, Daisaku ^d   Takimoto, Yukie ^d   Kamoto, Toshiyuki ^e   Ogawa, Osamu ^e   Sumiyoshi, Yoshiteru ^f   Shimazaki, Jun ^a   Kakizoe, Tadao ^b  

^a CHIBA UNIVERSITY   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL   (Japan)

^c OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

^d NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e KYOTO UNIVERSITY   (Japan)

^f NATIONAL HOSPITAL ORGANIZATION SHIKOKU CANCER CENTER   (Japan)

^g TOKYO KOSEI NENKIN HOSPITAL   (Japan)

Author keywords

External beam radiotherapy; Locally advanced; Prostate cancer; Radical prostatectomy; Randomized trial

Indexed keywords

ANTIANDROGEN; ESTROGEN; GONADORELIN AGONIST; HORMONE; PROSTATE SPECIFIC ANTIGEN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BIOCHEMISTRY; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER LOCALIZATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REDUCTION; DYSURIA; ERECTILE DYSFUNCTION; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; HUMAN; LINEAR ACCELERATOR; LONG TERM CARE; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MORBIDITY; ORCHIECTOMY; OVERALL SURVIVAL; PAINFUL DEFECATION; PELVIS LYMPH NODE; PROSTATE CANCER; PROSTATECTOMY; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; URINE INCONTINENCE; ADENOCARCINOMA; CANCER STAGING; COMPARATIVE STUDY; MEGAVOLTAGE RADIOTHERAPY; MULTIMODALITY CANCER THERAPY; PROSPECTIVE STUDY; PROSTATE TUMOR; QUALITY OF LIFE; QUESTIONNAIRE; RADIATION DOSE; TIME;

ADENOCARCINOMA; AGED; ANDROGEN ANTAGONISTS; COMBINED MODALITY THERAPY; FOLLOW-UP STUDIES; HUMANS; MALE; NEOPLASM STAGING; PROSPECTIVE STUDIES; PROSTATECTOMY; PROSTATIC NEOPLASMS; QUALITY OF LIFE; QUESTIONNAIRES; RADIOTHERAPY DOSAGE; RADIOTHERAPY, HIGH-ENERGY; TIME FACTORS;

EID: 33947513220     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyl115     Document Type: Article

References (31)

1. Epstein JI, Partin AW, Sauvageot J, Walsh PC. Prediction of progression following radical prostatectomy. A multivariate analysis of 721 men with long-term follow-up. Am J Surg Pathol 1996;20:286-92.
2. Gerber GS, Thisted RA, Scardino PT, Frohmuller HG, Schroeder FH, Paulson DF, et al. Results of radical prostatectomy in men with clinically localized prostate cancer. JAMA 1996;276:615-9.
3. Bagshaw MA, Cox RS, Hancock SL. Control of prostate cancer with radiotherapy: Long-term resuls. J. Urol 1994;152:1781-5.
4. Perez CA, Hanks GE, Leibel SA, Zietman AL, Fuks Z, Lee WR. Localized carcinoma of the prostate (states T1b, T1c, T2, and T3). Review or management with external beam radiation therapy. Cancer 1993;72:3156-73.
5. Kupelian PA, Elshaikh M, Reddy CA, Zippe C, Klein EA. Comparison of the efficacy of local therapies for localized prostate cancer in the prostate-specific antigen era: A large single-institution experience with radical prostatectomy and external-beam radiotherapy. J Clin Oncol 2002;20:3376-85.
6. Kupelian PA, Potters L, Khuntia D, Ciezki JP, Reddy CA, Reuther AM, et al. Radical prostatectomy, external beam radiotherapy <72 Gy, external beam radiotherapy ≥72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1-T2 prostate cancer. Int J Radiat Oncol Biol Phys 2004;58:25-33.
7. van den Ouden D, Davidson PJT, Hop W, Schroder FH. Radical prostatectomy as a monotherapy for locally advanced (stage T3) prostate cancer. J Urol 1994;151:646-51.
8. Akakura K, Furuya Y, Suzuki H, Komiya A, Ichikawa T, Igarashi T, et al. External beam radiation monotherapy for prostate cancer. Int J Urol 1999;6:408-13.
9. Ward JF, Slezak JM, Blute ML, Bergstralh EJ, Zincke H. Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome. BJU Int 2005;95:751-6.
10. Zagars GK, Johnson DE, von Eschenbach AC, Hussey DH. Adjuvant estrogen following radiation therapy for stage C adenocarcinoma of the prostate: long-term results of a prospective randomized study. Int J Radiat Oncol Biol Phys 1988;14:1985-91.
11. Isaka S, Shimazaki J, Akimoto S, Okada K, Yoshida O, Arai Y, et al. A prospective randomized trial for treating stages B2 and C prostate cancer: Radical surgery or irradiation with neoadjuvant endocrine therapy. Jpn J Clin Oncol 1994;24:218-23.
12. Akakura K, Isaka S, Akimoto S, Ito H, Okada K, Hachiya T, et al. Long-term results of a randomized trial for the treatment of stagess B2 and C prostate cancer: Radical prostatectomy versus external beam radiation therapy with a common endocrine therapy in both modalities. Urology 1977;54:313-8.
13. International Union Against Cancer (UICC). TNM Classification of Malignant Tumours, 4th edn. Berlin: Springer 1987.
14. Kuriyama M, Akimoto S, Akaza H, Arai Y, Usami M, Imai K, et al. Comparison of various assay systems for prostate-specific antigen standardization. Jpn J Clin Oncol 1992;22:393-9.
15. American Society for Therpeutic Radiology and Oncology Consensus Panel. Consensus statement: Guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys 1997;37:1035-41.
16. Paulson DF, Lin GH, Hinshaw W, Stephani S. Radical surgery versus radiotherapy for adenocarcinoma of the prostate. J Urol 1982; 128:502-4.
17. Bolla M, Collette L, Blank L, Warde P, Dubois JB, Mirimanoff R-O, et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): A phase III randomised trail. Lancet 2002;360:103-8.
18. Lawton CA, Winter K, Murray K, Machtay M, Mesic JB, Hanks GE, et al. Updated results of the phase III Radiation Therapy Oncology Group (RTOG) Trail 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2001;49:937-46.
19. Soloway MS, Pareek K, Sharifi R, Wajsman Z, McLeod D, Wood DP Jr, et al. Neoadjuvant androgen ablation before radical prostatectomy in cT2bNxM0 prostate cancer: 5-year result. J. Urol 2002;167:112-6.
20. Klotz LH, Goldenberg SL, Jewett MAS, Fradet Y, Nam R, Barkin J, et al. Long-term followup of a randomized trial of 0 versus 3 months of neoadjuvant androgen ablation before radical prostatectomy. J Urol 2003;170:791-4.
21. Messing EM, Manola J, Sarosdy M, Wilding G, Crawford ED, Trump D. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 1999;341: 1781-8.
22. Fair WR, Cookson MS, Stroumbakis N, Cohen D, Aprikian AG, Wang Y, et al. The indications, rationale, and results of neoadjuvant androgen deprivation in the treatment of prostatic cancer: Memorial Sloan-Kettering Cancer Center results. Urology 1997;49:46-55.
23. Akakura K, Akimoto S, Ohki T, Igarashi T, Murakami S, Shimazaki J, et al. Radiation therany for prostate cancer confined to pelvis. Int J Urol 1994;1:268-72.
24. Perez CA, Michalski J. Outcome of external-beam radiation therapy for localized carcinoma of the prostate (stages T1b, T2, and T3). In: Greco C, Zelefsky MJ, editors. Radiotherapy of Prostate Cancer. Amsterdam: Harwood Academic 2000;155-84.
25. Pollack A, Zagars GK, Starkschall G, Antolak JA, Lee JJ, Huang E, et al. Prostate cancer radiation dose response: Results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys 2002;53:1097-105.
26. Zelefsky MJ, Leibel SA, Gaudin PB, Kutcher GJ, Fleshner NE, Venkatramen ES, et al. Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer. Int J Radiat Oncol Biol Phys 1998;41:491-500.
27. Reinstein LE, Wang XH, Burman CM, Chen Z, Mohan Kutcher G, et al. A feasibility study of automated inverse treatment planning for cancer of the prostate. Int J Radiat Oncol Biol Phys 1998;40:207-14.
28. Akakura K, Tsujii H, Morita S, Tsuji H, Yagishita T, Isaka S, et al. Phase I/II clinical trial of carbon ion therapy for prostate cancer. Prostate 2004;58:252-8.
29. Labrie F, Candas B, Gomez JL, Cusan L. Can combined androgen blockade provide long-term control or possible cure of localized prostate cancer? Urology 2002;60:115-9.
30. Hachiya T, Akakura K, Saito S, Shinohara N, Sato K, Harada M, et al. A retrospective study of the treatment of locally advanced prostate cancer by six institutions in eastern and north-eastern Japan. BJU Int 2005;95:534-40.
31. Fowler JE Jr, Bigler SA, White PC, Duncan WL. Hormone therapy for locally advanced prostate cancer. J Urol 2002;168:546-9.